A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

LY3295668 erbumine had a manageable safety profile as monotherapy and in combination therapy. Although proof-of-concept clinical responses were observed, future studies with biomarker-selected populations and/or novel combinations may yield higher response rates with Aurora kinase A inhibition.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2025-02-11
DOI
https://doi.org/10.1002/cncr.35751
Citations
4
Primary Topic
Neuroblastoma Research and Treatments
Type
article
Field-Weighted Citation Impact
5.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

Steven G. DuBois, Nadège Corradini, C Karthik, Isabelle Aerts et al.
4 citations
Cancer
Neuroblastoma Research and Treatments
5.56
article

A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

Steven G. DuBois, Nadège Corradini, C Karthik, Isabelle Aerts, Lucas Moreno, Julie R. Park, Araz Marachelian, Emin Avşar, Yaël P. Mossé, Roberto Luksch, Brian Weiss, Lisa Howell, Anne L. Ryan, Bram De Wilde, Margaret E. Macy, Matthias Fischer, Jennifer H. Foster, Eunice Yuen, Kieuhoa T. Vo, Suzanne Shusterman, Alba Rubio‐San‐Simón, Chitose Ogawa
article en
4 citations

Abstract

LY3295668 erbumine had a manageable safety profile as monotherapy and in combination therapy. Although proof-of-concept clinical responses were observed, future studies with biomarker-selected populations and/or novel combinations may yield higher response rates with Aurora kinase A inhibition.

CancerVol. 131(4)
University of Southern California (US), Universitat Autònoma de Barcelona (ES), National Health Service (GB), St. Jude Children's Research Hospital (US), Children's Hospital of Philadelphia (US), Children's Hospital of Los Angeles (US), Harvard University (US), University of California, San Francisco (US), University of Cologne (DE), Baylor College of Medicine (US), Princess Margaret Hospital for Children (AU), Ghent University Hospital (BE), Riley Hospital for Children (US), Alder Hey Children's NHS Foundation Trust (GB), Eli Lilly (United Kingdom) (GB), Children's Hospital Colorado (US), Vall d'Hebron Institut de Recerca (ES), Centre Léon Bérard (FR), Hospital Infantil Universitario Niño Jesús (ES), Eli Lilly (India) (IN), Loxo Oncology at Lilly (United States) (US), UCSF Benioff Children's Hospital (US), Texas Children's Hospital (US), University Hospital Cologne (DE), Tokyo National Hospital (JP), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), Perth Children's Hospital, Indiana University School of Medicine, University of Colorado Anschutz Medical Campus (US), Indiana University – Purdue University Indianapolis (US), University of Pennsylvania (US), Institut Curie (FR), University of Colorado Denver (US)
Alex's Lemonade Stand Foundation for Childhood Cancer, Eli Lilly and Company
Good health and well-being
Openalex Percentile: Top 5%
Neuroblastoma Research and Treatments
5.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.